Pf Prism Cv Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PF PRISM CV, and what generic alternatives to PF PRISM CV drugs are available?
PF PRISM CV has sixteen approved drugs.
There are twenty-nine US patents protecting PF PRISM CV drugs.
There are six hundred and thirteen patent family members on PF PRISM CV drugs in sixty-six countries and seventy-two supplementary protection certificates in eighteen countries.
Summary for Pf Prism Cv
International Patents: | 613 |
US Patents: | 29 |
Tradenames: | 11 |
Ingredients: | 11 |
NDAs: | 16 |
Drugs and US Patents for Pf Prism Cv
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pf Prism Cv | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-001 | Feb 29, 2008 | AB | RX | Yes | No | 8,269,040 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
Pf Prism Cv | BOSULIF | bosutinib monohydrate | CAPSULE;ORAL | 217729-001 | Sep 26, 2023 | RX | Yes | No | 7,767,678*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-002 | Sep 4, 2012 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Pf Prism Cv | XALKORI | crizotinib | CAPSULE;ORAL | 202570-002 | Aug 26, 2011 | RX | Yes | Yes | 7,230,098 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Pf Prism Cv
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pf Prism Cv | XELJANZ | tofacitinib citrate | TABLET;ORAL | 203214-002 | May 30, 2018 | 7,842,699 | ⤷ Try a Trial |
Pf Prism Cv | RAPAMUNE | sirolimus | TABLET;ORAL | 021110-001 | Aug 25, 2000 | 5,100,899*PED | ⤷ Try a Trial |
Pf Prism Cv | TORISEL | temsirolimus | SOLUTION;INTRAVENOUS | 022088-001 | May 30, 2007 | RE44768*PED | ⤷ Try a Trial |
Pf Prism Cv | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-003 | Aug 20, 2014 | 6,673,838 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PF PRISM CV drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 0.5 mg and 1 mg | ➤ Subscribe | 2010-05-10 |
➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2016-11-07 |
➤ Subscribe | Tablets | 100mg and 500mg | ➤ Subscribe | 2016-09-06 |
➤ Subscribe | For Injection | 200 mg/vial | ➤ Subscribe | 2008-09-12 |
➤ Subscribe | Oral Suspension | 40 mg/mL | ➤ Subscribe | 2010-10-08 |
➤ Subscribe | Injection | 25 mg/mL, 1.8 mL vial | ➤ Subscribe | 2011-05-25 |
➤ Subscribe | Tablets | 0.5 mg | ➤ Subscribe | 2010-08-25 |
➤ Subscribe | Extended-release Tablets | 25 mg | ➤ Subscribe | 2015-05-08 |
➤ Subscribe | Tablets | 1 mg and 5 mg | ➤ Subscribe | 2018-02-23 |
➤ Subscribe | Tablets | 400 mg | ➤ Subscribe | 2018-10-15 |
➤ Subscribe | Tablets | 50 mg and 200 mg | ➤ Subscribe | 2008-04-14 |
➤ Subscribe | For Injection | 50 mg per vial | ➤ Subscribe | 2009-06-15 |
➤ Subscribe | Tablets | 1 mg and 2 mg | ➤ Subscribe | 2009-12-17 |
➤ Subscribe | Extended-release Tablets | 50 mg and 100 mg | ➤ Subscribe | 2012-02-29 |
International Patents for Pf Prism Cv Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Poland | 212108 | ⤷ Try a Trial |
European Patent Office | 1537859 | ⤷ Try a Trial |
China | 107750166 | ⤷ Try a Trial |
Hungary | 0200898 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Pf Prism Cv Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1786785 | 2013/009 | Ireland | ⤷ Try a Trial | PRODUCT NAME: PRODUCT (I.E. ACTIVE INGREDIENT OR COMBINATION OF ACTIVE INGREDIENTS) FOR WHICH A CERTIFICATE IS REQUESTED: CRIZOTINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE OR SOLVATE THEREOF; REGISTRATION NO/DATE: EU/1/12/793/001 EU/1/12/793/004 20121023 |
1666481 | PA2017025,C1666481 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: TOFACITINIBAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS PAVIDALE, ISKAITANT CITRATO DRUSKAAA; REGISTRATION NO/DATE: EU/1/17/1178 20170322 |
1218348 | 2013C/015 | Belgium | ⤷ Try a Trial | PRODUCT NAME: AXITINIB; AUTHORISATION NUMBER AND DATE: EU/1/12/777/001 20120905 |
0536515 | 06C0031 | France | ⤷ Try a Trial | PRODUCT NAME: TIGECYCLINE; REGISTRATION NO/DATE: EU/01/06/336/001 20060424 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.